Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Decramer

Showing results (91-100 of 201) with videos related to

Pageof 21
Sort By:
Respiratory Medicine|October 9, 2012
Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and BelgiumRobert Hettle, Hanne Wouters, Jon Ayres, et al.
Physical Therapy|April 11, 2015
Efficacy of a Novel Method for Inspiratory Muscle Training in People With Chronic Obstructive Pulmonary DiseaseDaniel Langer, Noppawan Charususin, Cristina Jácome, et al.
American Journal of Respiratory and Critical Care Medicine|January 25, 2005
Characteristics of physical activities in daily life in chronic obstructive pulmonary diseaseFabio Pitta, Thierry Troosters, Martijn A Spruit, et al.
Archives of Physical Medicine and Rehabilitation|September 27, 2005
Psychosocial conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive pulmonary diseaseJacob C Trappenburg, Thierry Troosters, Martijn A Spruit, et al.
Respiratory Research|July 8, 2016
Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studiesFrançois Maltais, Anne-Marie Kirsten, Alan Hamilton, et al.
Respiratory Physiology & Neurobiology|October 3, 2012
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsMarc Decramer, François Maltais, Gregory Feldman, et al.
Respiratory Medicine|May 3, 2011
Premature discontinuation during the UPLIFT studyMarc Decramer, Geert Molenberghs, Dacheng Liu, et al.
Respiratory Medicine|August 27, 2013
Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPDDonald P Tashkin, Ning Li, David Halpin, et al.
The New England Journal of Medicine|October 7, 2008
A 4-year trial of tiotropium in chronic obstructive pulmonary diseaseDonald P Tashkin, Bartolome Celli, Stephen Senn, et al.
Lung|June 17, 2011
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trialDavid M G Halpin, Marc Decramer, Bartolome Celli, et al.
Pageof 21

Showing results (91-100 of 201) with videos related to

Sort By:
Pageof 21
Respiratory Medicine|October 9, 2012
Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and BelgiumRobert Hettle, Hanne Wouters, Jon Ayres, et al.
Physical Therapy|April 11, 2015
Efficacy of a Novel Method for Inspiratory Muscle Training in People With Chronic Obstructive Pulmonary DiseaseDaniel Langer, Noppawan Charususin, Cristina Jácome, et al.
American Journal of Respiratory and Critical Care Medicine|January 25, 2005
Characteristics of physical activities in daily life in chronic obstructive pulmonary diseaseFabio Pitta, Thierry Troosters, Martijn A Spruit, et al.
Archives of Physical Medicine and Rehabilitation|September 27, 2005
Psychosocial conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive pulmonary diseaseJacob C Trappenburg, Thierry Troosters, Martijn A Spruit, et al.
Respiratory Research|July 8, 2016
Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studiesFrançois Maltais, Anne-Marie Kirsten, Alan Hamilton, et al.
Respiratory Physiology & Neurobiology|October 3, 2012
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsMarc Decramer, François Maltais, Gregory Feldman, et al.
Respiratory Medicine|May 3, 2011
Premature discontinuation during the UPLIFT studyMarc Decramer, Geert Molenberghs, Dacheng Liu, et al.
Respiratory Medicine|August 27, 2013
Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPDDonald P Tashkin, Ning Li, David Halpin, et al.
The New England Journal of Medicine|October 7, 2008
A 4-year trial of tiotropium in chronic obstructive pulmonary diseaseDonald P Tashkin, Bartolome Celli, Stephen Senn, et al.
Lung|June 17, 2011
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trialDavid M G Halpin, Marc Decramer, Bartolome Celli, et al.
Pageof 21